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PURPOSE Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)–
positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early 
measurements of tumor maximum standardized uptake value corrected for lean body mass (SULmax) on 18F-
labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) would predict 
pathologic complete response (pCR) to pertuzumab and trastuzumab (PT).
PATIENTS AND METHODS Patients with stage II or III, estrogen receptor–negative, HER2-positive breast cancer 
received four cycles of neoadjuvant PT. 18F-labeled fluorodeoxyglucose positron emission tomography-
computed tomography was performed at baseline and 15 days after PT initiation (C1D15). Eighty evaluable 
patients were required to test the null hypothesis that the area under the curve of percent change in SULmax by 
C1D15 predicting pCR is # 0.65, with a one-sided type I error rate of 10%.
RESULTS Eighty-eight women were enrolled (83 evaluable), and 85% (75 of 88) completed all four cycles of PT. 
pCR after PT alone was 22%. Receiver operator characteristic analysis of percent change in SULmax by C1D15 
yielded an area under the curve of 0.72 (80% CI, 0.64 to 0.80; one-sided P 5 .12), which did not reject the null 
hypothesis. However, between patients who obtained pCR and who did not, a significant difference in median 
percent reduction in SULmax by C1D15 was observed (63.8% v 41.8%; P 5 .004) and SULmax 
reduction $ 40% was more prevalent (83% v 52%; P 5 .03; positive predictive value, 31%). Participants not 
obtaining a 40% reduction in SULmax by C1D15 were unlikely to obtain pCR (negative predictive value, 91%).
CONCLUSION Although the primary objective was not met, early changes in SULmax predict response to PT in 
estrogen receptor–negative and HER2-positive breast cancer. Once optimized, this quantitative imaging strategy 
may facilitate tailoring of therapy in this setting.
J Clin Oncol 39:2247-2256. 
INTRODUCTION
Dual human epidermal growth factor receptor 2
(HER2)–directed therapy with pertuzumab and tras-
tuzumab (PT) in combination with chemotherapy is
more effective than trastuzumab and chemotherapy
for patients with HER2-positive breast cancer.1 The
NeoSPHERE and TRYPHAENA trials reported high
pathologic complete response (pCR) rates with the
dual approach, which led to the approval of neo-
adjuvant PT–based regimens in high-risk HER2-
positive breast cancer.2,3 Indeed, pCR is an ac-
cepted primary end point in neoadjuvant clinical trials
and can result in drug approval contingent on con-
firmatory results in the adjuvant setting.4 Data from
several studies have suggested that a proportion of
patients derive benefit from HER2-directed therapy
alone and may not require chemotherapy. The Neo-
SPHERE and Adjuvant Dynamic Marker-Adjusted
Personalized Therapy (ADAPT) trial investigators re-
ported pCR rates of approximately 30% for patients
with estrogen receptor (ER)–negative and HER2-
positive breast cancer who received neoadjuvant PT
without chemotherapy.2,5 Thus, the development of
predictive biomarkers that can identify a subgroup of
patients with HER2-positive breast cancer whomay be
treated with HER2-directed therapy alone and po-
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Changes in 18F-labeled fluorodeoxyglucose (FDG) uptake
on positron emission tomography (PET)-computed to-
mography (CT) as early as a few weeks after commence-
ment of neoadjuvant therapy have promise as a predictive
biomarker in early breast cancer.6,7 In the prospective
Neoadjuvant Lapatinib and/or Trastuzumab Treatment
Optimization (NeoALLTO) trial, changes in standardized
uptake value (SUV) on FDG-PET-CT were assessed as a
predictor of response to neoadjuvant HER2-directed
therapy.8 Patients were randomly assigned to a 6-week
biologic window of HER2-directed therapy alone (lapatinib
alone, trastuzumab alone, or lapatinib with trastuzumab)
followed by the addition of chemotherapy before surgery.9
Metabolic changes in breast tumors were detected as early
as 2 weeks after commencing HER2-directed therapy, and
pCR rates were found to be twice as high in patients who
were designated as responders compared with nonre-
sponders by FDG-PET-CT findings.10 Because chemo-
therapy was added after HER2-directed therapy in this trial,
concluding that early change in SUV would predict pCR to
HER2-directed therapy alone is not possible.
We hypothesized that early changes in maximum SUV
corrected for lean body mass (SULmax) on FDG-PET-CT
would correlate with pCR in patients with ER-negative,
HER2-positive breast cancer who receive neoadjuvant
PT, without chemotherapy. To test this hypothesis, we
performed a multicenter phase II study in which women
with stage II or III, ER-negative and HER2-positive breast
cancer received 12 weeks of neoadjuvant PT and incor-
porated serial FDG-PET-CT imaging and blood and tumor
biopsy collection.
Since the original publication of this manuscript,11 we
identified errors in the pathologic response data entry,
predominantly because of misclassification of ypT1a/
microinvasive disease as pCR. Reanalysis resulted in the
inability to reject the null hypothesis of the original study
design (the actions taken to address these errors can be
found in the Appendix, online only). The original publica-
tion has been retracted,12 and this updated manuscript
provides the corrected results.
PATIENTS AND METHODS
Eligibility
Eligible women were 18 years of age or older with untreated
histologically proven infiltrating carcinoma of the breast and
clinical stage T2-4(a-c), any N, and M0 disease (American
Joint Committee on Cancer 7th edition staging). Tumors
must have ER # 10% and be HER2-positive13 by local
pathology review. An Eastern Cooperative Oncology Group
performance status 0-1, a left ventricular ejection
fraction $ 50%, and adequate organ function were re-
quired. Patients agreed to baseline and follow-up FDG-
PET-CT and study-specific procedures with no minimum
SULmax of primary breast cancer required for eligibility.
Patients also signed a written informed consent approved
by the institutional review boards of the participating
institutions.
Study Design
Participants received 12 weeks of neoadjuvant PT (Ap-
pendix Fig A1, online only). Pertuzumab (supplied by
Genentech, South San Francisco, CA) was administered
every 3 weeks (840 mg loading dose and then 420 mg),
and trastuzumab every 3 weeks (8 mg/kg loading dose and
then 6 mg/kg), both intravenously. Dose modification was
not permitted.
FDG-PET-CT was performed before research tumor biop-
sies, at baseline, and at day 15 after commencement of
CONTEXT
Key Objective
The primary objective of TBCRC026 was to correlate baseline and early percentage change (by C1D15) in maximum
standardized uptake value corrected for lean body mass (SULmax) (breast) on fluorodeoxyglucose (FDG)-positron
emission tomography-computed tomography with pathologic complete response to neoadjuvant pertuzumab and
trastuzumab (without chemotherapy) in estrogen receptor–negative and human epidermal growth factor receptor 2–
positive breast cancer.
Knowledge Generated
Although the primary objective did not meet the predefined statistical boundaries, the data indicate that early changes in
SULmax on FDG-PET predict response to four cycles of pertuzumab and trastuzumab in this setting, ie, an absence of
40% decline in SULmax by C1D15 is associated with a lower likelihood of achieving pathologic complete response
(negative predictive value, 91%).
Relevance
The TBCRC026 results suggest that optimized FDG-positron emission tomography-computed tomography quantitative
imaging–based biomarkers may facilitate intensification and de-intensification of neoadjuvant therapy pending further
evaluation.
therapy (C1D15). Tumor tissue was obtained from the
surgical specimen on the day of surgery for research
purposes. Plasma samples were obtained at baseline and
C1D15, post-treatment or presurgery, and postsurgery
(Appendix Fig A1). Common Terminology Criteria for Ad-
verse Events (version 4.0) were used to grade toxicity.
Neoadjuvant HER2-directed therapy and chemotherapy,
given after study treatment with PT and before definitive
surgery, was allowed per physician discretion if incomplete
response or disease progression is observed (Appendix
Fig A1). Taxane-based chemotherapy with PT was rec-
ommended. Tumor biopsy to confirm the presence of re-
sidual disease histologically (ie, no pCR) was required
before additional chemotherapy to ensure data available for
primary end point. Axillary evaluation and type of breast
surgery performed were per surgeon discretion. Postop-
erative systemic therapy and radiation per standard of care
were recommended.
18F-FDG PET-CT
Participants underwent FDG-PET-CT at baseline and
C1D15 (3-day window). Approval of FDG-PET-CT facilities
included provision of study manual to sites, review of
representative clinical scans, and phantom images. After a
60-minute uptake phase following intravenous FDG in-
jection, a combined FDG-PET-CT scan was obtained from
midskull to midfemur in general conformance with the
Uniform Protocols for Imaging in Clinical Trials FDG-PET-
CT and Radiological Society of North America Quantitative
Imaging Biomarkers Alliance profiles.14 Scans were
transmitted digitally, and central review and quantitation
were performed by readers blinded to clinical data.6
Measurements were acquired by placing an all-
encompassing spherical volume of interest over the tar-
get primary breast cancer tissue and recording SULmax,
with care taken not to include adjacent normal FDG-avid
tissue. SULmax was collected because it is more consistent
than SUV in normal tissues from patient to patient, being
less weight dependent.15 SULmax of primary breast cancer
is reported in this analysis (primary end point).
Statistical Considerations
The primary objective was to correlate baseline and early
percentage change (by C1D15) in SULmax on FDG-PET-
CT of the primary breast cancer with pCR after four cycles of
neoadjuvant PT. pCR was defined as no viable invasive
cancer in breast and axilla by local pathology review. All
other patients were classified as non-pCR, including those
with histologically confirmed residual disease after
12 weeks of PT or clinical progression on PT. An early
stopping rule was in place to suspend or terminate the
study if the proportion of clinical progression exceeded
10%.
To be evaluable for the primary analysis, both baseline and
C1D15 FDG-PET-CT scan was performed, SULmax data
were collected, and pCR status after PT was evaluated. The
study was powered to test the null hypothesis that the area
under the receiver operating characteristic (ROC) curve of
percent of change in SULmax at C1D15, a measure used to
quantify the overall predictive power of the biomarker,
was# 0.65. Eighty evaluable patients with a projected pCR
rate of 25%would have an 81% or greater power to detect a
true area under the curve (AUC) of 0.80 against the null
hypothesis (an AUC # 0.65 at a one-sided type I error rate
of 0.10). The AUC measures how well the biomarker dis-
criminates between responders (those obtaining pCR) and
nonresponders (no pCR), with a greater AUC indicating
higher diagnostic accuracy. The 80% CIs for AUC were
reported to align with the one-sided primary hypothesis test
at 10% type 1 error and obtained by means of U-Statistics
theory.16 A sample size of up to 88 patients was planned to
account for nonevaluable cases. Safety analysis included
patients who received at least one dose of any study drug
and was based on the frequency of adverse events (AEs).
Continuous variables were listed by means, standard de-
viations, and medians and ranges and were compared
between patients who obtained pCR and those who did not
using Wilcoxon rank-sum tests. Binary outcomes were
listed by proportions and binomial exact CIs and compared
using Fisher’s exact tests. ROCs with SULmax parameters
as the predictor were generated with the goal of identifying
the SULmax cut point that maximized the sum of sensitivity
and specificity. We correlated baseline, C1D15, and per-
cent reduction in SULmax with pCR using logistic regres-
sions. We evaluated positive predictive value and negative
predictive value (NPV) for predicting pCR with selected
cutoffs.
All other statistical tests, unless otherwise stated, were two-
sided and considered statistically significant at P , .05.
The analyses were carried out using R version 3.4.2 soft-
ware packages.17 The research Protocol (online only) and
article were written by the authors and reviewed by the
pharmaceutical funders; the funders had no access to the
study database and were not involved in the study analysis
or interpretation of results.
RESULTS
Patient Characteristics
From January 2014 to August 2017, 88 women enrolled in
the study across nine sites. The median age was 58 years
(range, 29-82 years), and the median tumor size was
3.7 cm (range, 2-15 cm) by standard imaging (Table 1). Of
these women, 83 were evaluable for the primary analysis
(Fig 1). All four cycles of PT were completed in 85% of
cases (75 of 88), and all 83 evaluable patients underwent
the primary surgery. Twenty-five patients (28%) received
neoadjuvant nonstudy therapy (Fig 1) and were classified
as not obtaining pCR in the intention-to-treat (ITT) analysis.
Of note, 22 of these 25 patients met the definition of his-
tologically confirmed residual disease after 12 weeks of PT
and/or clinical progression on study therapy. Additional
nonstudy neoadjuvant therapy included taxane and
carboplatin-based (n 5 17), and taxane-based (n 5 7)
therapy with PT, and one patient received a fifth cycle of PT.
Two patients also received anthracycline-based neo-
adjuvant chemotherapy.
Treatment Safety and Efficacy
AEs were as expected for this regimen (Appendix Table A1,
online only). Grade 3 AEs included diarrhea (8%), ana-
phylaxis (1%), and left ventricular systolic dysfunction
(1%).
pCR was observed in 22% of patients after four cycles of PT
alone (18 of 83; 95% CI, 13 to 32). The assumption that
those who withdrew consent did not obtain pCR led to a
conservative estimate of 20% for pCR (18 of 88; 95%CI, 13
to 30). Of the patients who had histologically confirmed
residual disease after 12 weeks of PT or clinical progression
and received additional neoadjuvant nonstudy therapy,
32% (seven of 22) had pCR at the time of surgery. Seven
(8%) experienced clinical progression on study therapy
after two to four cycles (median, three cycles) of PT, and the
study did not meet the early stopping rule because the
proportion of clinical progression did not exceed 10%.
Baseline and Change in Biomarkers and Correlation With
Response to Therapy
All 88 enrolled patients underwent baseline and C1D15
FDG-PET-CT. The same scanner at each site was used for
baseline and C1D15 scan in 90% of cases, with repre-
sentative images provided (Appendix Fig A2, online only).
The mean injected FDG dose was 10.92 6 2.3 mCi FDG.
The mean radiotracer uptake time was 646 11.5 minutes.
Four patients subsequently withdrew consent, and one
patient had incomplete data, preserving 83 evaluable cases
for the ITT analysis. Summary statistics for baseline,
C1D15, and percent change in SULmax are provided in
Appendix Table A2 (online only). Baseline SULmax was not
significantly associated with pCR (Table 2). ROC analysis of
baseline SULmax yielded an AUC value of 0.57 (80% CI,
0.46 to 0.69) for discriminating patients with and without
pCR (Fig 2). Univariable logistic regression suggested that
baseline SULmax is negatively associated with the odds of
obtaining pCR, although the association did not reach
statistical significance (Table 3).
We observed a significant difference in median percent
reduction in SULmax by C1D15 between patients who
obtained pCR and those who did not (63.8% v 41.8%;
P 5 .004; Table 2; Fig 3), and the univariable logistic
regression estimated an odds ratio (OR) of 1.03 (95% CI,
1.01 to 1.06) associated with each additional 1% reduction
in SULmax (Table 3). Similar results were observed in
multivariable logistic regression that also adjusted for age,
grade, and tumor size (Appendix Table A3, online only).
TABLE 1. Patient Characteristics
Characteristic N 5 88, No. (%)
Age, years













Baseline clinical tumor size, cm

























Breast conserving therapy 33 (37)
NA 4 (5)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NA, not
available; SD, standard deviation.
The ROC analysis, with percent reduction in SULmax as the
predictor, yielded an AUC of 0.72 (80% CI, 0.64 to 0.80;
P 5 .12) in the evaluable patients, thus not rejecting the
null hypothesis for the primary end point (Fig 2). The ex-
ploratory cutoff of $ 40% versus , 40% reduction in
SULmax yielded a sensitivity of 83% and a specificity of
48% for identifying patients who obtained pCR. Compared
with other cut points examined, including the cutoff value of
52.5% reduction determined on the basis of Youden’s
index,18 the threshold of 40% is considered clinically op-
timal for its high NPV (91%) for pCR (ie, declines in
SUV, 40% predict lack of pCR; Appendix Table A4, online
only).
Based on emerging knowledge regarding the role of FDG-
PET-CT in assessing response to anticancer therapy and
recognition that a minimum uptake of FDG at baseline is
required to allow identification of a meaningful decline in
tracer uptake from baseline, as is now incorporated into the
PERCIST 1.0 criteria, an exploratory subset analysis was
performed by excluding patients with low FDG avidity tu-
mors (n5 7), defined as baseline tumor SULmax, 2. The
subgroup ROC analysis (n5 76), with percent reduction in
SULmax as the predictor, yielded an AUC of 0.78 (80% CI,
0.71 to 0.86; P 5 .01), rejecting the null hypothesis of
AUC # 0.65. The exploratory cutoff in this case of $ 50%
versus , 50% reduction in SULmax yielded a sensitivity of
Surgery directly after
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  Adverse events (n = 2)
  Patient or provider decision (n = 4)
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FIG 1. Study flow diagram. Study treatment 5 PT. aAll patients remained evaluable. bReasons for withdrawal of
consent include one participant refused further participation after C1D1, one participant refused further par-
ticipation after C2D1, one patient refused further participation after study treatment was completed, and one
patient withdrew consent because of unacceptable toxicity. PT, pertuzumab and trastuzumab.
93% and a specificity of 53% for identifying patients
obtaining pCR. Compared with other cut points examined,
including the cutoff value of 52.5% reduction determined
based on Youden’s index,18 the threshold of 50% is con-
sidered clinically optimal for its high NPV (97%) for pCR (ie,
declines in SUV , 50% predict lack of pCR; Appendix
Table A5, online only).
Among the 83 evaluable patients, a significant difference
was observed in median C1D15 SULmax between patients
who obtained pCR and those who did not (1.6 v 3.6;
P , .001; Table 2; Fig 3), and the univariable logistic
regression estimated an OR of 0.43 (95% CI, 0.23 to 0.79)
for a one-unit increase in C1D15 SULmax (Table 3). The
association remained statistically significant after adjusting
for age, grade, and tumor size (Appendix Table A3). The
exploratory ROC analysis, with C1D15 SULmax as the
predictor, yielded an AUC of 0.77 (80% CI, 0.70 to 0.83;
P 5 .009; Fig 2). The cutoff of # 3 versus . 3 in C1D15
SULmax yielded a high NPV for pCR over other cut points
and maximized Youden’s index. A significantly higher
proportion of C1D15 SULmax# 3 was observed in patients
who obtained pCR versus those who did not (100% v 45%;
P , .001). NPV and positive predictive value for pCR
associated with this retrospectively determined threshold
were 100% and 38%, respectively.
Multivariable logistic regression that adjusted for baseline
SULmax and percent reduction in SULmax revealed that
C1D15 SULmax remained significantly predictive of pCR
(adjusted OR, 0.26; 95% CI, 0.09 to 0.70; Table 3). The
inclusion of age, grade, and tumor size in the regression
model did not change the predictive value of the PET
parameters (Appendix Table A3). Tumor stage was not
included in the analysis because no patients with stage III
disease obtained pCR.
Among the 22 patients who received a subsequent addition
of nonstudy neoadjuvant therapy (Fig 1), a predefined
exploratory analysis was performed to correlate SULmax
with pCR. Baseline, median percent reduction, and C1D15
SULmax were not significantly associated with pCR in this
small patient population (Appendix Table A6, online only).
DISCUSSION
In the TBCRC026 trial, we investigated whether early
changes in SULmax on FDG-PET-CT can predict pCR after
HER2-directed therapy with PT alone (no chemotherapy) in
ER-negative, HER2-positive early-stage breast cancer. In
an ITT analysis, our study did not reject the null hypothesis
related to the AUC of percent change in SULmax by C1D15.
However, we demonstrated that a percent reduction in
TABLE 2. Baseline, D15, and Percent Change in SULmax Between pCR and No
pCR
Variable pCR (n 5 18) No pCR (n 5 65) P a
Baseline SULmax
Mean (SD) 6.7 (4.6) 7.2 (3.8)
Median (range) 5.6 (1.6-15.8) 6.7 (1.7-14.6) .35
D15 SULmax
Mean (SD) 1.7 (0.6) 4.6 (3.9)
Median (range) 1.6 (0.9-2.8) 3.6 (0.6-15.9) , .001
SULmax # 3, n (%) 18 (100) 29 (45) , .001
Percent reduction in
SULmax
Mean (SD) 62.9 (21.3) 38.3 (32.2)
Median (range) 63.8 (25.1-91.5) 41.8 (234.9 to 91.9) .004
$ 40% reduction, n (%) 15 (83) 34 (52) .03
Abbreviations: D15, day 15; pCR, pathologic complete response; SD, standard
deviation; SULmax, maximum standardized uptake value corrected for lean body
mass.
aWilcoxon rank-sum test for comparing continuous variables and Fisher’s exact
test for comparing binary variables.
TABLE 3. Univariable and Multivariable Analysis of Association of SULmax With Pathologic Response
Variable
Univariable Analysis Multivariable Analysis
OR (95% CI) P Adjusted OR (95% CI) P Adjusted OR (95% CI) P
Baseline SULmax 0.96 (0.84 to 1.11) .59 1.32 (0.97 to 1.79) .07 1.45 (1.01 to 2.06) .04
D15 SULmax 0.43 (0.23 to 0.79) .007 0.26 (0.09 to 0.70) .008 0.22 (0.07 to 0.67) .008
Percent reduction SULmax 1.03 (1.01 to 1.06) .006 0.98 (0.94 to 1.02) .27 0.97 (0.93 to 1.02) .24
D15 SULmax , 3 v . 3a — —
Percent reduction SULmax $ 40% v , 40% 4.56 (1.20 to 17.3) .03
Age, decades 1.07 (0.70 to 1.62) .76 0.98 (0.55 to 1.74) .94
Grade 3 v 2 0.78 (0.24 to 2.54) .68 0.74 (0.17 to 3.31) .70
Baseline tumor size, cm 0.56 (0.35 to 0.91) .02 0.53 (0.29 to 0.94) .03
NOTE. Intent-to-treat analysis.
Abbreviations: D15, day 15; OR, odds ratio; pCR, pathologic complete response; SULmax, maximum standardized uptake value corrected for lean body
mass.
aUnivariate logistic regression with D15 SULmax # 3 as a predictor is broken because all these patients were responders (pCR).
SULmax by C1D15 and C1D15 SULmax was significantly
different between patients who obtained pCR after four
cycles of PT and those who did not. ROC analysis revealed a
higher proportion of SULmax reduction of $ 40% in those
who obtained pCR with high sensitivity (83%) and NPV
(91%). The exploratory analysis of C1D15 SULmax # 3
may have an even greater sensitivity (100%) and NPV
(100%) as a predictor of pCR. Because 56% of evaluable
patients had C1D15 SULmax # 3, both biomarkers have
the potential to be useful early response assessment tools.
Finally, an exploratory subset analysis supports the ex-
clusion of patients with low FDG avidity tumors at baseline
(SULmax , 2) from the primary analysis of future studies
evaluating functional change in FDG uptake after the first
cycle of therapy.
Our results suggest that optimized FDG-PET-CT quantita-
tive imaging–based biomarkers may facilitate intensifica-
tion and de-intensification of neoadjuvant therapy.
Because of a high NPV, reduction in SULmax on FDG-PET-
CT during the first cycle of PT may predict most optimally
those patients who will not achieve pCR with PT alone and
should be recommended alternative regimens in future
clinical trials. One can consider an analogy to our most
important predictive biomarkers in breast cancer, where
ER- and HER2-negative phenotypes have a very high NPV
for lack of benefit from targeted therapies.13,19
We previously reported that early change in SULmax on
FDG-PET-CT by C1D15 after initiating neoadjuvant che-
motherapy is successful in predicting pCR in patients with
HER2-negative breast cancer.6 A limited number of studies
have been performed in patients with HER2-positive breast
cancer. In patients receiving trastuzumab emtansine for
metastatic disease, a combination of results of pretreat-
ment HER2–PET-CT with [89Zr]trastuzumab with those of
early FDG-PET-CT metabolic response assessment
(baseline and before the second cycle of trastuzumab
emtansine) showed promise in predicting response.20 The
NeoALLTO substudy identified that metabolic changes
detected on FDG-PET-CT in early-stage breast tumors
2 weeks after commencing HER2-directed therapy predict
for pCR rates that are two fold higher in metabolic re-
sponders compared with nonresponders by imaging cri-
teria.8 The TBCRC026 trial, however, aimed to identify an
optimal SULmax cut point that could help predict response
to PT. This is in contrast to the NeoALLTO substudy that
used a predefined cut point for response per European
Organisation for Research and Treatment of Cancer im-
aging criteria at 2 weeks (. 15% reduction in SUV), which
may not represent the most optimal cut point in the study
population to predict response and may be below the re-
producibility limits of sequential quantitative 18F-FDG-PET-
CT studies.10
PT in combination with chemotherapy is now a standard of
care in the high-risk early breast cancer setting yet can be
associated with serious toxicities.21 Investigators have thus
attempted to de-escalate therapy. For example, 12 weeks
of adjuvant paclitaxel and 1 year of trastuzumab were
associated with high survival rates among women with
small, node-negative HER2-positive breast cancer.22
Chemotherapy-free approaches have also been investi-
gated using dual HER2-directed therapy, concurrent with
endocrine therapy for those with ER-positive cancers.5,23,24
Pertuzumab- or lapatinib-based approaches demonstrate
similar pCR rates to the 22% rate that we observed with














































FIG 2. Receiver operating characteristic curves for (A) baseline
and (B) percent of change in SULmax and (C) 15 days after PT
initiation (C1D15). AUC, area under the curve; PT, pertuzumab
and trastuzumab; SULmax, maximum standardized uptake value
corrected for lean body mass.
neoadjuvant PT alone in this ER-negative, HER2-positive
subtype.
Studies in the neoadjuvant setting are ideal for investigation of
promising predictors of sensitivity to HER2-directed therapy.
In the PAMELA trial, investigators administered 18 weeks of
neoadjuvant lapatinib and trastuzumab (and endocrine
therapy if ER-positive) in patients with HER2-positive early
breast cancer. Stromal tumor–infiltrating lymphocytes and
tumor cellularity at C1D15 were independently associated
with pCR.25 TheHER2-enriched intrinsic subtype (defined by
PAM50) was also identified as a potential predictor of pCR.23
In a study that investigated 12 weeks of lapatinib and tras-
tuzumab, TBCRC006 investigators reported that activation of
the phosphoinositide 3-kinase pathway is associated with
resistance to therapy.26 Approaches that use a combination
of imaging-/blood-/ and tissue-based biomarkersmay provide
the most optimal biomarker of response to HER2-directed
therapy without chemotherapy.
Strengths of our study include its multicenter prospective
design and inclusion of a homogenous group of patients with
ER-negative, HER2-positive breast cancer. We chose the
C1D15 time point for the second FDG-PET-CT scan to define
as early as possible in the treatment course of those patients
who might require an alternative approach. The exploratory
single C1D15 time point appears promising as a predictive
biomarker that if confirmed would indicate that baseline
imaging may not be required. Limitations of our study in-
clude the identification of baseline primary tumor SULmax
value below liver reference value (mean1 23 standardized
deviation, n 5 4 patients), which may affect accurate
measurement of percent change in SULmax.15 These pa-
tients were included in our original analysis as they were
eligible per protocol, but may be excluded in future studies.
This approach to biomarker development that incorporates
FDG-PET-CT is feasible across multiple sites, is less in-
vasive than performing a tumor biopsy for biomarker
evaluation, and has been shown to be useful in other tumor
types.27,28 We identified percentage change and C1D15
cutoffs for SULmax that best predict resistance to HER2-
directed therapy with PT and will design prospective
studies in which we will determine the clinical utility of
altering therapy based on early changes in SULmax. We will
also investigate other imaging parameters including those
described in the PET Response Criteria in Solid Tumors
version 1.0.15
In conclusion, the results have the potential to provide a
more individualized approach to neoadjuvant therapy in
women with stage II or III, ER-negative and HER2-positive
breast cancer. Such an approach could identify patients
who may receive HER2-directed therapy alone and be
spared chemotherapy as well as those who require an
aggressive approach.
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FIG 3. Box plots of (A) 15 days after PT initiation (C1D15), and (B) percent reduction in SULmax in
patients with pCR versus no pCR. The horizontal line inside the box shows the median. The lower and
upper hinges of the box represent the 25th and 75th percentiles, respectively. The circles represent
actual values of D15 and percent reduction in SULmax. pCR, pathologic complete response; PT,
pertuzumab and trastuzumab; SULmax, maximum standardized uptake value corrected for lean body
mass.
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APPENDIX
Supplementary Methods
Corrective actions taken to ensure accuracy of data presented in the
revised manuscript titled “Updated Results of TBCRC026: Phase II
Trial Correlating Standardized Uptake Value With Pathological Com-
plete Response to Pertuzumab and Trastuzumab in Breast Cancer”
(10.1200/JCO.21.00280).
As stated in the retraction notice,12 errors in pathologic complete
response (pCR) data were identified in the original publication of the
TBCRC026 study.11 These errors related to data entry in the study
master database, predominantly because of misclassification of ypT1a
and microinvasive disease as pCR. A second independent pathologist
was asked to independently review all pathology reports, and ulti-
mately, 10 cases required reclassification from pCR to no pCR.
Since uncovering these findings in late May 2020, our study team has
taken the following actions to rectify this issue:
1. Reports for all pathology cases were independently reviewed
by two breast cancer pathologists. The second pathologist had
not been previously involved with the trial.
2. The primary and secondary end point data were reanalyzed by
the study statistician.
3. The revised data and proposed revisions to the manuscript
were independently reviewed by the lead statistician for the
Translational Breast Cancer Research Consortium.
4. The revised data were also assessed by the group statistician
for a proposed imaging study that will independently validate
the findings from TBCRC026 published in Journal of Clinical
Oncology (JCO).
5. The revised analysis and proposed corrections in the pub-
lished JCO manuscript were presented to the TBCRC Exec-
utive Committee in preparation of our submission of these
materials to JCO.
6. As a result of this experience, the TBCRC leadership is
reviewing procedures related to the analyses of primary ob-
jectives of its trials, to provide assurance that clinical trial
investigators approve of all data related to trial conduct and
reporting.
Reanalysis of the data has shown that we are now unable to reject the
null hypothesis as outlined in the predefined analysis plan for the
primary objective. Although the primary objective did not meet the
predefined statistical boundaries, the data continue to show that the
absence of early change in maximum standardized uptake value
corrected for lean body mass is associated with a lower likelihood of
achieving pathologic complete response after four cycles of
pertuzumab/trastuzumab in early-stage human epidermal growth
factor receptor 2–positive breast cancer, and the observed negative
predictive value assessed as part of the primary objective remains
essentially unchanged.
We believe that the revised primary results of this study (10.1200/
JCO.21.00280) remain critical for investigators initiating clinical trials
with similar treatment or end points. Finally, an exploratory subset
analysis included in the revised manuscript provides important sup-
portive data for the PERCIST 1.0 criteria of excluding low baseline

































PET imaging Blood sampling Tumor biopsy
FIG A1. TBCRC026 study schema. CR, complete response; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PET, positron
emission tomography; PR, progesterone receptor.




FIG A2. Sample 18F-FDG PET images (baseline and D15) in patients (A and B) with and (C and D) without
pCR. 18F-FDG, 18F-labeled fluorodeoxyglucose; pCR, pathologic complete response; PET, positron emission
tomography.











Diarrhea 80 (91) 74 (84) 6 (7) 0
Fatigue 30 (34) 30 (34) 0 0
Nausea 24 (27) 24 (27) 0 0
Rash 17 (19) 17 (19) 0 0
Headache 13 (15) 13 (15) 0 0
Anorexia 13 (15) 13 (15) 0 0
Mucositis 12 (14) 12 (14) 0 0
Chills 10 (11) 10 (11) 0 0
Dysgeusia 6 (7) 6 (7) 0 0
Pruritus 5 (6) 5 (6) 0 0
Dyspepsia 5 (6) 5 (6) 0 0
NOTE. N 5 88.
TABLE A2. SULmax Summary Statistics
SULmax (n 5 83) Mean SD Min Median Max
Baseline 7.1 3.9 1.6 6.7 15.8
D15 3.9 3.7 0.6 2.4 15.9
Percent changea 43.6 31.7 234.9 52.5 91.9
Abbreviations: D15, day 15; max, maximum; min, minimum; SD,
standard deviation; SULmax, maximum standardized uptake value
corrected for lean body mass.
aPercent change in SUL 5 21(D15 SUL 2 baseline SUL)/baseline
SUL.
TABLE A3. Adjusted ORs of Baseline, D15, and Percent Reduction in SULmax, Adjusting for Age, Grade, and Tumor Size in a Separate Multivariable Logistic
Regression
Variable Adjusted OR (95% CI) P Adjusted OR (95% CI) P Adjusted OR (95% CI) P
Baseline SULmax 1.0 (0.85 to 1.17) .99
D15 SULmax 0.43 (0.22 to 0.85) .02
Percent reduction 1.03 (1.01 to 1.06) .009
Age 0.94 (0.59 to 1.50) .79 0.85 (0.51 to 1.43) .54 0.94 (0.56 to 1.56) .80
Grade 0.86 (0.23 to 3.21) .82 0.94 (0.24 to 3.77) .93 0.62 (0.16 to 2.45) .50
Tumor size 0.56 (0.34 to 0.91) .02 0.60 (0.36 to 0.98) .04 0.55 (0.32 to 0.94) .03
Abbreviations: D15, day 15; OR, odds ratio; SULmax, maximum standardized uptake value corrected for lean body mass.
TABLE A4. Performance of SULmax (D15 and Percent Reduction) as a Screening Test With Different Cutoff Values
SULmax Sensitivity, % (90% CI) Specificity, % (90% CI) NPV, % (90% CI) PPV, % (90% CI) OR (%) P
D15 (n 5 83)
# 2.5 89 (69 to 98) 60 (49 to 70) 95 (85 to 99) 38 (26 to 52) 12 , .001
# 3 100 (85 to 100) 55 (45 to 66) 100 (92 to 100) 38 (26 to 51) — —
# 3.5 100 (85 to 100) 51 (40 to 62) 100 (91 to 100) 36 (25 to 49) — —
Percent reductiona (n 5 83)
$ 40 83 (62 to 95) 48 (37 to 59) 91 (79 to 98) 31 (20 to 43) 4.6 .01
$ 50 78 (56 to 92) 54 (43 to 65) 90 (78 to 96) 32 (20 to 45) 4.1 .02
$ 55 61 (39 to 80) 65 (54 to 75) 86 (75 to 93) 32 (19 to 48) 2.9 .05
NOTE. OR for C1D15 SULmax # 3 (and # 3.5) is infinity as all individuals with C1D15 SULmax . 3 did not achieve pCR.
Abbreviations: D15, day 15; NPV, negative predictive value; OR, odds ratio; pCR, pathologic complete response; PPV, positive predictive value; SULmax,
maximum standardized uptake value corrected for lean body mass.
aPercentage of change in SUL 5 21(D15 SUL 2 baseline SUL)/baseline SUL.
TABLE A5. Performance of SULmax (D15 and Percent Reduction) as a Screening Test With Different Cutoff Values (Subset Analysis Excluding Patients With
Baseline SULmax , 2)
SULmax Sensitivity, % (90% CI) Specificity, % (90% CI) NPV, % (90% CI) PPV, % (90% CI) OR (%) P
D15 (n 5 76)
# 2.5 87 (64 to 98) 64 (53 to 74) 95 (85 to 99) 37 (24 to 52) 11.5 , .001
# 3 100 (82 to 100) 59 (48 to 70) 100 (92 to 100) 38 (25 to 52) — —
# 3.5 100 (82 to 100) 54 (43 to 65) 100 (91 to 100) 35 (23 to 49) — —
Percent reductiona (n 5 76)
$ 40 93 (72 to 100) 46 (35 to 57) 97 (85 to 100) 30 (19 to 43) 11.9 .002
$ 50 93 (72 to 100) 53 (41 to 64) 97 (86 to 100) 33 (21 to 46) 15.4 , .001
$ 55 73 (49 to 90) 64 (53 to 74) 91 (80 to 97) 33 (20 to 49) 4.9 .009
NOTE. OR for C1D15 SULmax # 3 (and # 3.5) is infinity as all individuals with C1D15 SULmax . 3 did not achieve pCR.
Abbreviations: D15, day 15; NPV, negative predictive value; OR, odds ratio; pCR, pathologic complete response; PPV, positive predictive value; SULmax,
maximum standardized uptake value corrected for lean body mass.
aPercentage of change in SUL 5 21(D15 SUL 2 baseline SUL)/baseline SUL.
TABLE A6. Baseline, D15, and Percent Change in SULmax Between pCR and No
pCR in Patients With Residual Disease After Study Therapy and Subsequent
Addition of Nonstudy Neoadjuvant Therapy
Variable pCR (n 5 7) No pCR (n 5 15) P a
Baseline SULmax
Mean (SD) 8.0 (4.4) 9.0 (4.1)
Median (range) 7.6 (1.7-13.9) 8.4 (2.6-14.6) .57
D15 SULmax
Mean (SD) 5.5 (5.4) 7.8 (4.9)
Median (range) 4.4 (0.7-14.4) 6.6 (2.0-15.9) .18
Percent reduction in
SULmax
Mean (SD) 41.4 (31.9) 14.1 (31.0)
Median (range) 36.9 (23.2 to 79.6) 21.6 (234.9 to 70.0) .09
Abbreviations: D15, day 15; pCR, pathologic complete response; SD, standard
deviation; SULmax, maximum standardized uptake value corrected for lean body
mass.
aWilcoxon rank-sum test for comparing continuous variables.
